Download PDF
Klin Padiatr 2004; 216(3): 150-156
DOI: 10.1055/s-2004-822627
Therapieoptimierung

© Georg Thieme Verlag Stuttgart · New York

The Concept of the GPOH-HD 2003 Therapy Study for Pediatric Hodgkin's Disease: Evolution in the Tradition of the DAL/GPOH Studies

Konzept der Therapieoptimierungsstudie GPOH-HD 2003 für die Behandlung von Kindern und Jugendlichen mit einem Morbus Hodgkin: Evolution aus der Tradition der DAL/GPOH-StudienD. Körholz1 , A. Claviez9 , D. Hasenclever5 , R. Kluge3 , W. Hirsch2 , F. Kamprad4 , W. Dörffel8 , L. Wickmann8 , K. Papsdorf4 , K. Dieckmann7 , T. Kahn2 , C. Mauz-Körholz1 , C. Dannenberg1 , R. Pötter7 , O. Brosteanu6 , G. Schellong10 , O. Sabri3 , 11
  • 1Division of Pediatric Hematology and Oncology, Clinic and Policlinic for Children and Adolescents, University of Leipzig Medical Center, Germany
  • 2Department of Radiology, University of Leipzig Medical Center, Germany
  • 3Department of Nuclear Medicine, University of Leipzig Medical Center, Germany
  • 4Department of Radiotherapy,University of Leipzig Medical Center, Germany
  • 5Institute for Biomathematics and Epidemiology, University of Leipzig, Germany
  • 6Center for Coordination of Clinical Studies, University of Leipzig, Germany
  • 7Department of Radiotherapy, Vienna General Hospital, Austria
  • 8Department of Pediatrics, HELIOS Klinikum Berlin-Buch, Germany
  • 9Department of Pediatrics, University of Kiel, Germany
  • 10Department of Pediatrics, University of Muenster Medical Center, Germany
  • 11for the GPOH-HD Study Group
Further Information

Publication History

Publication Date:
03 June 2004 (online)

Also available at
    Permissions and Reprints

Abstract

Today it is possible to cure more than 90 % of children and adolescents with Hodgkin's disease with a combination of radiotherapy and chemotherapy. Since the DAL-HD 82 study, the main scientific focus has been on avoiding late effects such as the OPSI syndrome, late complications involving the heart, lungs, thyroid and/or gonads particularly sterility in men and premature onset of menopause in women, and the prevention of secondary malignancies. The GPOH-HD 2003 study will introduce FDG-PET to the initial diagnostic program and the assessment of response to therapy in order to evaluate further possibilities for reducing therapy. In this context, the central review of all clinical and radiological findings, systematically done since the DAL-HD 90 study, will be increasingly relevant in maintaining standardised stage classification and therapy group assignment which was established by the preceding studies. Continuing in the direction of the earlier studies, the indications for radiotherapy will be restricted even further. In the early stages (treatment group 1) patients with CR or a negative FDG-PET at the end of chemotherapy will receive no radiotherapy in order to reduce the risk of a secondary malignancy. In a randomized comparison, procarbazine will be replaced by dacarbazine in the COPP cycles to determine whether sterility in men and premature onset of menopause in women can be avoided by elimination of procarbazine while retaining the same clinical efficacy. Finally, relapse therapy is to be tailored according to the time of relapse, the initial therapy group, and the patient's response to the relapse therapy with more patients receiving autologous transplantation in order to further improve the results of relapse treatment.

Zusammenfassung

Durch die kombinierte Radio-Chemotherapie können über 90 % aller Kinder und Jugendlichen mit einem Morbus Hodgkin geheilt werden. Seit der DAL-HD-82-Studie steht die Vermeidung von Langzeittherapiefolgen - u. a. OPSI-Syndrom, Spätschäden am Herzen, der Lunge, der Schilddrüse und den Gonaden, und hier insbesondere die Unfruchtbarkeit beim Mann/vorzeitige Menopause bei der Frau sowie die Vermeidung von Sekundärmalignomen - im Blickpunkt des wissenschaftlichen Interesses. In der GPOH-HD-2003-Studie wird die FDG-PET in das initiale Diagnostikprogramm und in die Beurteilung des Therapieansprechens eingeführt, um weitere Möglichkeiten zur Therapiereduktionen zu evaluieren. In diesem Zusammenhang wird die seit der DAL-HD-90-Studie systematisch eingeführte Referenzbegutachtung aller klinischen und radiologischen Untersuchungsbefunde weiter an Bedeutung gewinnen, um die in den bisherigen Studien erreichte Vereinheitlichung der Stadieneinteilung und der Therapiegruppenzuordnung zu erhalten. Der Tradition der Studiengruppe folgend soll die Indikation zur Radiotherapie weiter eingeschränkt werden. In der Therapiegruppe 1, d. h. den frühen Stadien, erhalten die Patienten mit CR oder einer negativen FDG-PET am Ende der Chemotherapie keine Radiotherapie. Hierdurch soll das Risiko für die Entstehung von Sekundärmalignomen gesenkt werden. In den COPP-Zyklen wird Procarbazin im randomisierten Vergleich durch Dacarbazin ersetzt. Hierdurch soll geprüft werden, ob bei gleicher onkologischer Wirksamkeit die Unfruchtbarkeit beim Mann bzw. die vorzeitige Menopause bei der Frau durch den Verzicht auf Procarbazin vermieden werden kann. Auf der Basis der bisherigen Rezidivbehandlungen soll schließlich die Rezidivtherapie nach Zeitpunkt des Rezidives, initialer Therapiegruppe und Ansprechen auf die Rezidivtherapie gesteuert werden.

Key words

Hodgkin's disease - children - GPOH - FDG-PET radiotherapy - dacarbazine

Schlüsselwörter

Morbus Hodgkin - Kinder - GPOH - FDG-PET - Dakarbazin

References

  • 1 Montravers F, McNamara D, Landman-Parker J, Grahek D, Kerrou K, Younsi N, Widland M, Leverger G, Talbot J N. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.  Eur J Nucl Med Mol Imaging. 2002;  29 1155-1165
    CrossrefPubMedGoogle Scholar
  • 2 Partridge S, Timothy A, O'Doherty M J, Hain S F, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution.  Ann Oncol. 2000;  11 1273-1279
    CrossrefPubMedGoogle Scholar
  • 3 Weihrauch M R, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, Textoris F, Ansen S, Franklin J, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease.  Ann Hematol. 2002;  81 20-25
    CrossrefPubMedGoogle Scholar
  • 4 Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, Moser E, Glatting G, Kotzerke J, Guhlmann C A, Schirrmeister H, Reske S N. 2-(fluorine-18)Fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma.  Cancer. 2001;  91 889-899
    CrossrefPubMedGoogle Scholar
  • 5 Dieckmann K, Potter R, Wagner W, Prott F J, Hörnig-Franz I, Rath B, Schellong G. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90.  Radiother Oncol. 2002;  62 191-200
    CrossrefPubMedGoogle Scholar
  • 6 Stumpe K DM, Urbinelli M, Steinert H C, Glanzmann C, Buck A, von Schulthess G K. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography.  Eur J Nucl Med. 1998;  25 721-728
    CrossrefPubMedGoogle Scholar
  • 7 Lang O, Bihl H, Hültenschmidt B, Sautter-Bihl M L. Clinical relevance of positron emission tomography in treatment control and relapse of Hodgkin's disease.  Strahlenther und Onkol. 2001;  177 138-144
    PubMedGoogle Scholar
  • 8 de Wit M, Bohuslavizki K H, Buchert R, Bumann D, Clausen M, Hossfeld D K. 18-FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma.  Ann Oncol. 2001;  12 29-37
    PubMedGoogle Scholar
  • 9 Weihrauch M R, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, Bohlen H, Wolf J, Schicha H, Diehl V, Tesch H. Thoracic positron emission tomography using 18F fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.  Blood. 2001;  98 2930-2934
    CrossrefPubMedGoogle Scholar
  • 10 Spaepen K, Stoobants S, Dupont P, Thomas J, Vandenberghe P, Blazarini J, de Wolf-Peeters C, Mortelmans L, Verhoef G. Can positron emission tomography with 18F fluorodeoxyglucose after first line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?.  Brit J Hematol. 2001;  115 272-278
    PubMedGoogle Scholar
  • 11 Naumann R, Vaić A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke W G, Ehninger G. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma.  Brit J Haematol. 2001;  115 793-800
    PubMedGoogle Scholar
  • 12 Dittmann H, Sölkler M, Kollmannsberger C, Dohmen B M, Baumann C, Kopp A, Bares R, Claussen C D, Kanz L, Bokemeyer C. Comparison of 18FDG-PET and CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.  Oncology reports. 2001;  8 1393-1399
    PubMedGoogle Scholar
  • 13 Körholz D, Kluge R, Wickmann L, Hirsch W, Lüders H, Lotz I, Dannenberg C, Hasenclever D, Dörffel W, Sabri O. Importance of F18-Fluorodeoxy-D-2-Glucose positron Emission Tomography (FDG-PET) for Staging and Therapy Control of Hodgkin's Lymphoma in childhood and adolescence - Consequences for the GPOH-HD 2003 protocol.  Onkologie. 2003;  26 489-493
    CrossrefPubMedGoogle Scholar
  • 14 Bhatia S, Robison L L, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows A T. Breast cancer and other second neoplasms after childhood Hodgkin's disease.  N Engl J Med. 1996;  334 745-751
    CrossrefPubMedGoogle Scholar
  • 15 Bhatia S, Yasui Y, Robinson L L, Birch J M, Bogue M K, Diller L, DeLa C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann F B, Tersak J, Meadows A T. Late effekt Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report of the late effects study group.  J Clin Oncol. 2003;  21 4386-4394
    CrossrefPubMedGoogle Scholar
  • 16 Schellong G, Waubke-Landwehr A K, Langermann H J, Riehm H J, Brämswig J, Ritter J. Prediction of splenic involvement in children with Hodgkin's disease. Significance of clinical and intraoperative findings. A retrospective statistical analysis of 154 patients in the German therapy study DAL-HD-78.  Cancer. 1986;  57 2049-2056
    CrossrefPubMedGoogle Scholar
  • 17 Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze E W, Wickmann L. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.  Klin Pädiatr. 2003;  215 139-145
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Schellong G, Brämswig J, Ludwig R, Gerein V, Jobke A, Jürgens H, Kabisch H, Stollmann B, Weinel P, Gadner H. et al . [Combined treatment strategy in over 200 children with Hodgkin's disease: graduated chemotherapy, involved field irradiation with low dosage and selective splenectomy. A report of the cooperative therapy study DAL-HD-82].  Klin Pädiatr. 1986;  198 137-146
    PubMedGoogle Scholar
  • 19 Nachman J B, Sposto R, Herzog P, Gilchrist G S, Wolden S L, Thomson J, Kadin M E, Pattengale P, Davis P C, Hutchinson R J, White K. Children's Cancer Group . Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.  J Clin Oncol. 2002;  20 3765-3771
    CrossrefPubMedGoogle Scholar
  • 20 Wickmann L, Lüders H, Dörffel W. 18-FDG-PET findings in children and adolescents ith Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and the predictive value of follow-up examinations.  Klin Pädiatr. 2003;  215 146-150
    PubMedGoogle Scholar
  • 21 Young H, Baum R, Cremerius U, Herholz K, Hoeckstra O, Lammertsma A A, Pruim J, Price P. for the European Organization for research and Treatment of Cancer (EORTC) PET Study Group . Measurement of clinical and subclinical tumour response unsing 18-F-Fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations.  Eur J Cancer. 1999;  35 1773-1782
    CrossrefPubMedGoogle Scholar
  • 22 Dörffel W, Lüders H, Marciniak H, Parwaresch R, Schwarze E W, Wickmann L, Rühl U. Results of the multicenter trial GPOH-HD 95 for treatment of Hodgkin's disease in children and adolescents.  Monatsschr Kinderheilkd. 2002;  150 1294
    PubMedGoogle Scholar
  • 23 Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, Gaitini D, Kolodny G M, Israel O. Hodgkin disease: Prediction of outcome with 67 Ga scintigraphy after one cycle of chemotherapy.  Radiology. 1999;  210 487-491
    PubMedGoogle Scholar
  • 24 Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Bull U. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.  Nuklearmedizin. 2001;  40 23-30
    PubMedGoogle Scholar
  • 25 Kostakoğlu L, Coleman M, Leonard J P, Kuji I, Zoe H, Goldsmith S J. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.  J Nucl Med. 2002;  43 1018-1027
    PubMedGoogle Scholar
  • 26 Schellong G, Hörnig I, Brämswig J, Bökkerink J PM, Steinhoff A, Ludwig R, Niethammer D, Reiter A, Lengerke J, v Heinecke H, Schwarze E W, Pötter R, Müller R P, Wannenmacher M. Zur Bedeutung des Procarbazins in der Chemotherapie des Morbus Hodgkin - Ein Bericht der kooperativen Therapiestudie DAL-HD-85.  Klin Pädiatr. 1988;  200 205-213
    PubMedGoogle Scholar
  • 27 Brämswig J H, Heimes U, Heiermann E, Schlegel W, Nieschlag E, Schellong G. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence.  Cancer. 1990;  65 1298-1302
    CrossrefPubMedGoogle Scholar
  • 28 Hassel J U, Bramswig J H, Schlegel W, Schellong G. [Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin's disease. Results in 25 patients of the DAL-HD-85 study].  Klin Pädiatr. 1991;  203 268-272
    PubMedGoogle Scholar
  • 29 Schellong G, Bramswig J H, Hornig-Franz I, Schwarze E W, Potter R, Wannenmacher M. Hodgkin's disease in children: combined modality treatment for stages I A, I B, and II A. Results in 356 patients of the German/Austrian Pediatric Study Group.  Ann Oncol. 1994;  5 (Suppl 2) 113-115
    PubMedGoogle Scholar
  • 30 Schellong G, Potter R, Brämswig J, Wagner W, Prott F J, Dorffel W, Körholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze E W. The German-Austrian Pediatric Hodgkin's Disease Study Group . High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90.  J Clin Oncol. 1999;  17 3736-3744
    CrossrefPubMedGoogle Scholar
  • 31 Gerres L, Bramswig J H, Schlegel W, Jurgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin's disease.  Cancer. 1998;  83 2217-2222
    CrossrefPubMedGoogle Scholar
  • 32 Schellong G, Riepenhausen M. Spätfolgen nach Morbus Hodkin bei Kindern und Jugendlichen: ergebnisse der Studien DAL-HD 78-HD 90. Projektbericht 2002
    Google Scholar
  • 33 Byrne J, Fears T R, Gail M H, Pee D, Connelly R R, Austin D F, Holmes G F, Holmes F F, Latourette H B, Meigs J W. et al . Early menopause in long-term survivors of cancer during adolescence.  Am J Obstet Gynecol. 1992;  166 788-793
    PubMedGoogle Scholar
  • 34 Kreuser E D, Xiros N, Hetzel W D, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease.  J Cancer Res Clin Oncol. 1987;  113 260-266
    CrossrefPubMedGoogle Scholar
  • 35 Frei E, Luce J K, Talley R W, Vaitkevicius V K, Wilson H E. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma.  Cancer Chemother Rep. 1972;  56 667-670
    PubMedGoogle Scholar
  • 36 Klener P, Donner L. Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas.  Acta haemat. 1977;  57 272-278
    PubMedGoogle Scholar
  • 37 Schellong G, Hörnig-Franz I. Salvage therapy results in childhood Hodgkin's disease. In: Zander AR, Barlogie B (eds). Autologous bone marrow transplantation for Hodgkin's lymphoma and multiple myeloma. Springer, Berlin, Heidelberg 1993; 8-10
    Google Scholar
  • 38 Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, Boissevain F, Zschaber R, Muller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone A H, Diehl V. German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation . Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.  Lancet. 2002;  359 2065-2071
    CrossrefPubMedGoogle Scholar
  • 39 Baker K S, Gordon B G, Gross T G, Abromowitch M A, Lyden E R, Lynch J C, Vose J M, Armitage J O, Coccia P F, Bierman P J. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents.  J Clin Oncol. 1999;  17 825-831
    PubMedGoogle Scholar
  • 40 Williams C D, Goldstone A H, Pearce R, Green S, Armitage J O, Carella A, Meloni G. Autologous bone marrow transplantation for pediatric Hodgkin's disease: A case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry.  J Clin Oncol. 1993;  11 2243-2249
    PubMedGoogle Scholar
  • 41 Schmitz N, Glass B, Dreger P, Haferlach T, Horst H A, Ollech-Chwoyka J, Suttorp M, Gassmann W, Loffler H. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.  Ann Hematol. 1993;  66 251-256
    CrossrefPubMedGoogle Scholar
  • 42 Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix H T, Karanikas G, Potzi C, Raderer M, Dudczak R, Kletter K. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.  Leukemia. 2002;  16 260-267
    CrossrefPubMedGoogle Scholar
  • 43 Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner H H, Dorken B, Hossfeld D K, Diehl V, Engert A. Participating Centers . Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.  Ann Oncol. 2002;  13 1628-1635
    CrossrefPubMedGoogle Scholar

D. KörholzMD 

Division of Pediatric Hematology and Oncology · Clinic and Policlinic for Children and Adolescents · University of Leipzig Medical Center

Oststr. 21-25

04317 Leipzig

Germany

Phone: +49/3 41-9 72 61 51

Fax: +49/3 41-9 72 61 59

Email: koerd@medizin.uni-leipzig.de